Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Airsupra Demonstrates Significant Reduction in Severe Exacerbations in Asthma Patients
Details : Airsupra (albuterol/budesonide) formerly known as PT027, is a first-in-class SABA/ICS. It is being investigated in patients with intermittent or mild persistent asthma.
Product Name : Airsupra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2024
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Airsupra Now Available as FDA-Approved Anti-Inflammatory Asthma Rescue Option
Details : Airsupra (albuterol/budesonide) formerly known as PT027, is a first-in-class SABA/ICS. It is now available as the first and only FDA-approved anti-inflammatory rescue option for asthma.
Product Name : PT027
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2024
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Launch Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Teva And Launch Therapeutics Collaborates For Dual-Action Asthma Rescue Inhaler Program
Details : The collaboration aims to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for asthma.
Product Name : TEV-56248
Product Type : Steroid
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Launch Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Abingworth
Deal Size : $150.0 million
Deal Type : Financing
Teva, Launch Therapeutics Partner for Dual-Action Asthma Inhaler Development
Details : The net proceeds will be used to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for asthma.
Product Name : TEV-56248
Product Type : Steroid
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Abingworth
Deal Size : $150.0 million
Deal Type : Financing
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Avillion LLP
Deal Size : Inapplicable
Deal Type : Inapplicable
Airsupra (PT027) Approved in the US for Asthma
Details : Airsupra (albuterol/budesonide), is a first-in-class SABA/ICS rescue treatment for asthma in the US. It is an inhaled, fixed-dose combination of albuterol, a SABA, and budesonide, and has been developed in a pMDI using AstraZeneca’s Aerosphere delivery...
Product Name : PT027
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Avillion LLP
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
Details : Albuterol sulfate inhalation powder is first and only breath-actuated, digital SABA inhaler, which is used for prevention of bronchospasm related to exercise-induced or reversible obstructive airway disease.
Product Name : Proair HFA-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2023
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ProAirDigihaler (albuterol sulfate) inhalation powder is first and only breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record and store objective data showing how often and how well patients use their rescue inhaler, measur...
Product Name : ProAir Digihaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Avillion LLP
Deal Size : Inapplicable
Deal Type : Inapplicable
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
Details : PT027 (albuterol/budesonide) is a potential first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the US containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhale...
Product Name : PT027
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2022
Lead Product(s) : Salbutamol Sulphate,Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Avillion LLP
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study evaluated the effect of ProAir Digihaler System on asthma control versus standard of care as measured by Asthma Control Test, and explored use of the ProAir Digihaler System to help support patient-physician interactions for asthma management versu...
Product Name : ProAir Digihaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2022
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Result showed adults and children aged 13 and older with uncontrolled asthma using ProAir Digihaler (albuterol sulfate) and integrated system had 85.3% higher odds of improving their asthma control after 3 months compared with those using standard-of-car...
Product Name : ProAir Digihaler
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable